What is the current stock price of Mirum Pharmaceuticals, Inc. (MIRM)?

As of the latest market data, Mirum Pharmaceuticals, Inc. (MIRM) is trading at $98.62. The stock has seen a loss of -2.04% today.

Does Mirum Pharmaceuticals, Inc. (MIRM) pay a dividend?

Based on current data, Mirum Pharmaceuticals, Inc. does not have a confirmed active dividend policy.

What is the market cap of Mirum Pharmaceuticals, Inc.?

The current market capitalization of Mirum Pharmaceuticals, Inc. (MIRM) is approximately unavailable.

MIRM

Mirum Pharmaceuticals, Inc.·Healthcare

98.62

2.036%(−2.05)

Market Closed

108.36

9.876%(+9.74)

After Hours

Last Updated: — ET

52W L: $43.3052W H: $114.99

MIRM NEWS

businesswire.com

2d ago

Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026.

marketbeat.com

3d ago

Mirum Pharma: A Rare Disease Growth Story to Watch

Mirum Pharmaceuticals NASDAQ: MIRM is a late-stage biotechnology company that is making significant progress toward its mission to combat rare diseases with no or limited treatment options. Mirum recently reported its Q1 2026 earnings, headlined by 43% year-over-year (YOY) revenue growth.

businesswire.com

May 14

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

businesswire.com

May 12

Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes.

businesswire.com

May 12

Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering.

seekingalpha.com

May 12

Mirum Pharmaceuticals: A Rare Disease Platform Becoming Bigger Than Its First Franchise

Mirum Pharmaceuticals is evolving into a rare disease commercialization platform with multiple late-stage assets and robust commercial execution. MIRM raised 2026 net product sales guidance to $660–$680M, reflecting strong visibility and momentum, especially from LIVMARLI and bile acid products. The BlueJay acquisition and late-stage programs in HDV, PSC, and FOP create a catalyst-rich period, supporting the premium valuation versus sector peers.

Company Profile

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.

Sector

Healthcare

Industry

Biotechnology

Employees

334

IPO Date

2019-07-18

Beta

0.52

Websitewww.mirumpharma.com↗